The therapeutic phase I trial of the recombinant native HIV-1 Tat protein

Barbara Ensoli, Valeria Fiorelli, Fabrizio Ensoli, Adriano Lazzarin, Raffaele Visintini, Pasquale Narciso, Aldo Di Carlo, Paolo Monini, Mauro Magnani, Enrico Garaci

Research output: Contribution to journalArticlepeer-review

Abstract

The native HIV-1 Tat protein was chosen as a vaccine candidate based on its key role in the virus life cycle and on the correlation of Tat-specific immune responses with the asymptomatic stage and lower disease progression rates, but also due to its sequence conservation amongst the various HIV clades as well as the adjuvant effects on dendritic cells. Safety, immunogenicity and efficacy data in monkeys support the development of this vaccine concept.

Original languageEnglish
Pages (from-to)2207-2209
Number of pages3
JournalAIDS (London, England)
Volume22
Issue number16
DOIs
Publication statusPublished - 2008

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The therapeutic phase I trial of the recombinant native HIV-1 Tat protein'. Together they form a unique fingerprint.

Cite this